<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02532647</url>
  </required_header>
  <id_info>
    <org_study_id>CNS7056-015</org_study_id>
    <nct_id>NCT02532647</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of Remimazolam in ASA III and IV Patients Undergoing Colonoscopy</brief_title>
  <official_title>A Study Evaluating the Safety and Efficacy of Remimazolam (CNS 7056) Compared to Placebo and Midazolam in ASA III and IV Patients Undergoing Colonoscopy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Paion UK Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Premier Research Group plc</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Paion UK Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A prospective, double-blind, randomized, placebo and active controlled, multi-center,
      parallel group study comparing remimazolam to placebo, with an additional open-label arm for
      midazolam, in American Society of Anesthesiologists (ASA) Grade III and IV patients (ASA
      status evaluated by an anesthesiologist not otherwise involved in the study) undergoing a
      colonoscopy for diagnostic or therapeutic reasons.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 2015</start_date>
  <completion_date type="Actual">December 2016</completion_date>
  <primary_completion_date type="Actual">December 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Success Rates of the Procedure</measure>
    <time_frame>From first dose of study drug until the end of colonoscopy</time_frame>
    <description>The success of the procedure, as measured by completion of the colonoscopy procedure, AND no requirement for a rescue sedative medication, AND no requirement of more than 5 doses of study medication within any 15 minute window. (For midazolam: 3 doses within any 12 minute window)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to Start of Procedure</measure>
    <time_frame>From the first administration of the study drug to the beginning of the colonoscopy</time_frame>
    <description>The time from the first administration of the study drug to the beginning of the colonoscopy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Fully Alert</measure>
    <time_frame>From the last injection of the study drug AND from end of colonoscopy until the patient has recovered to fully alert</time_frame>
    <description>Time to first of 3 Modified Observer's Assessment of Alertness/Sedation (MOAA/S) scores of 5 after the end of colonoscopy procedure (colonoscope out) and after the last injection of study drug</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">79</enrollment>
  <condition>Colonoscopy</condition>
  <arm_group>
    <arm_group_label>Remimazolam</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Remimazolam 2.5 - 5.0 mg initially, followed by 1.25 - 2.5 mg top-up doses as required to maintain sedation.
Fentanyl pre-treatment: 25-50 μg (or less for elderly/disabled subjects), and 25 μg top-up doses</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Midazolam</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Midazolam 1.0 mg initially, followed by 0.5 mg top-up doses as required to maintain sedation.
Fentanyl pre-treatment: 25-50 μg (or less for elderly/disabled subjects), and 25 μg top-up doses</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo administered in double-blind manner.
Fentanyl pre-treatment: 25-50 μg (or less for elderly/disabled subjects), and 25 μg top-up doses</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Remimazolam</intervention_name>
    <arm_group_label>Remimazolam</arm_group_label>
    <other_name>CNS7056</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Midazolam</intervention_name>
    <arm_group_label>Midazolam</arm_group_label>
    <other_name>Versed</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male and female patients, aged ≥18, scheduled to undergo a diagnostic or therapeutic
             colonoscopy (therapeutic procedures may include hemostasis, resection, ablation
             decompression, and foreign body extraction, for example).

          2. ASA grade III/IV

               1. ASA III patients are patients with severe systemic disease eg patients who, in
                  the judgment of the Principal Investigator (PI), have significant enough systemic
                  disease to warrant performing the colonoscopy procedure only in a facility which
                  has post-procedure inpatient capability. ASA III physical status classification
                  encompasses a wide range of potential patient co-morbidities some of which may
                  make the selection of a facility with post-procedure inpatient capability
                  preferable. By definition, ASA III patients have one or more moderate to severe
                  systemic diseases which potentially cause substantial functional limitation.
                  Examples may include poorly controlled diabetes or hypertension, moderate to
                  severe chronic obstructive pulmonary disease, active hepatitis, heart failure or
                  coronary artery disease (including implanted pacemaker and/or stent, recent
                  myocardial infarction) cerebrovascular accident, or end stage renal disease
                  requiring dialysis.

               2. ASA IV patients are patients with severe systemic disease that is a constant
                  threat to life eg at least one severe disease that is poorly controlled or at end
                  stage; possible risk of death; unstable angina; symptomatic chronic obstructive
                  pulmonary disease; symptomatic chronic heart failure; hepatorenal failure.

          3. For all female patients, negative result of urine or serum pregnancy test.
             Additionally, for women with child-bearing potential only, use of birth control during
             the study period (from the time of consent until all specified observations are
             completed).

          4. Patient voluntarily signs and dates an informed consent form (ICF) that is approved by
             an investigational review board (IRB) prior to the conduct of any study procedure.

          5. Patient is willing and able to comply with study requirements and will be available
             for a Follow-up Visit on Day 1 (+ 1 day) and Follow-up Phone call (Day 4 +/- 3 days)
             after the colonoscopy.

        Exclusion Criteria:

          1. Patients with a known sensitivity to benzodiazepines, flumazenil, opioids, naloxone,
             or a medical condition such that these agents are contraindicated.

          2. Female patients with a positive pregnancy test at screening or baseline and lactating
             female patients.

          3. Patients clearly acutely intoxicated with alcohol or drugs of abuse at baseline.

          4. Patients in receipt of any investigational drug within 30 days or less than 7
             half-lives (whichever is longer) before Screening, or scheduled to receive one during
             the study period.

          5. Participation in any previous clinical trial with remimazolam.

          6. Patients with an inability to communicate well with the Investigator, or deemed
             unsuitable according to the Investigator (in each case providing a reason).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Jupiter Medical Center</name>
      <address>
        <city>Jupiter</city>
        <state>Florida</state>
        <zip>33458</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Indiana University Division of Gastroenterology/Hepatology</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>51000</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Delta Research Partners Inc</name>
      <address>
        <city>Monroe</city>
        <state>Louisiana</state>
        <zip>71201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2018</verification_date>
  <study_first_submitted>August 19, 2015</study_first_submitted>
  <study_first_submitted_qc>August 25, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 26, 2015</study_first_posted>
  <results_first_submitted>December 14, 2018</results_first_submitted>
  <results_first_submitted_qc>January 17, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">January 23, 2019</results_first_posted>
  <disposition_first_submitted>April 17, 2018</disposition_first_submitted>
  <disposition_first_submitted_qc>April 17, 2018</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">April 18, 2018</disposition_first_posted>
  <last_update_submitted>January 17, 2019</last_update_submitted>
  <last_update_submitted_qc>January 17, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">January 23, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Midazolam</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Remimazolam</title>
          <description>Remimazolam 2.5 - 5.0 mg initially, followed by 1.25 - 2.5 mg top-up doses as required to maintain sedation.</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Placebo administered in double-blind manner.</description>
        </group>
        <group group_id="P3">
          <title>Midazolam</title>
          <description>Midazolam 1.0 mg initially, followed by 0.5 mg top-up doses as required to maintain sedation.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="32"/>
                <participants group_id="P2" count="16"/>
                <participants group_id="P3" count="31"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Safety Population</title>
              <participants_list>
                <participants group_id="P1" count="31"/>
                <participants group_id="P2" count="16"/>
                <participants group_id="P3" count="30"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="31"/>
                <participants group_id="P2" count="16"/>
                <participants group_id="P3" count="30"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Did not receive trial medication</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Baseline Analysis Population is the Safety Population</population>
      <group_list>
        <group group_id="B1">
          <title>Remimazolam</title>
          <description>Remimazolam 2.5 - 5.0 mg initially, followed by 1.25 - 2.5 mg top-up doses as required to maintain sedation.</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Placebo administered in double-blind manner.</description>
        </group>
        <group group_id="B3">
          <title>Midazolam</title>
          <description>Midazolam 1.0 mg initially, followed by 0.5 mg top-up doses as required to maintain sedation.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="31"/>
            <count group_id="B2" value="16"/>
            <count group_id="B3" value="30"/>
            <count group_id="B4" value="77"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="63.1" spread="8.65"/>
                    <measurement group_id="B2" value="63.0" spread="8.37"/>
                    <measurement group_id="B3" value="61.5" spread="10.60"/>
                    <measurement group_id="B4" value="62.5" spread="9.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>&lt;65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="19"/>
                    <measurement group_id="B4" value="46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>≥65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="11"/>
                    <measurement group_id="B4" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="16"/>
                    <measurement group_id="B4" value="34"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="14"/>
                    <measurement group_id="B4" value="43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="31"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="30"/>
                    <measurement group_id="B4" value="77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Height</title>
          <units>cm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="171.1" spread="10.07"/>
                    <measurement group_id="B2" value="171.8" spread="7.72"/>
                    <measurement group_id="B3" value="168.4" spread="10.32"/>
                    <measurement group_id="B4" value="170.2" spread="9.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Weight</title>
          <units>kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="91.0" spread="28.14"/>
                    <measurement group_id="B2" value="94.0" spread="26.11"/>
                    <measurement group_id="B3" value="87.9" spread="23.91"/>
                    <measurement group_id="B4" value="90.4" spread="25.90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Mass Index (BMI)</title>
          <units>Kg/m2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30.9" spread="8.28"/>
                    <measurement group_id="B2" value="30.8" spread="5.53"/>
                    <measurement group_id="B3" value="30.8" spread="6.75"/>
                    <measurement group_id="B4" value="30.8" spread="7.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>American Society of Anesthesiologists (ASA) Classification</title>
          <description>ASA Class III: Severe systemic disease. ASA Class IV: Severe systemic disease that is constant threat to life</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>ASA Class III</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="15"/>
                    <measurement group_id="B4" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ASA Class IV</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="15"/>
                    <measurement group_id="B4" value="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Success Rates of the Procedure</title>
        <description>The success of the procedure, as measured by completion of the colonoscopy procedure, AND no requirement for a rescue sedative medication, AND no requirement of more than 5 doses of study medication within any 15 minute window. (For midazolam: 3 doses within any 12 minute window)</description>
        <time_frame>From first dose of study drug until the end of colonoscopy</time_frame>
        <population>All patients who were randomised, and analysed as randomised.</population>
        <group_list>
          <group group_id="O1">
            <title>Remimazolam</title>
            <description>Remimazolam 2.5 - 5.0 mg initially, followed by 1.25 - 2.5 mg top-up doses as required to maintain sedation.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo administered in double-blind manner.</description>
          </group>
          <group group_id="O3">
            <title>Midazolam</title>
            <description>Midazolam 1.0 mg initially, followed by 0.5 mg top-up doses as required to maintain sedation.</description>
          </group>
        </group_list>
        <measure>
          <title>Success Rates of the Procedure</title>
          <description>The success of the procedure, as measured by completion of the colonoscopy procedure, AND no requirement for a rescue sedative medication, AND no requirement of more than 5 doses of study medication within any 15 minute window. (For midazolam: 3 doses within any 12 minute window)</description>
          <population>All patients who were randomised, and analysed as randomised.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="31"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Start of Procedure</title>
        <description>The time from the first administration of the study drug to the beginning of the colonoscopy</description>
        <time_frame>From the first administration of the study drug to the beginning of the colonoscopy</time_frame>
        <population>Patients who did not reach the endpoint are excluded from this analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Remimazolam</title>
            <description>Remimazolam 2.5 - 5.0 mg initially, followed by 1.25 - 2.5 mg top-up doses as required to maintain sedation.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo administered in double-blind manner.</description>
          </group>
          <group group_id="O3">
            <title>Midazolam</title>
            <description>Midazolam 1.0 mg initially, followed by 0.5 mg top-up doses as required to maintain sedation.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Start of Procedure</title>
          <description>The time from the first administration of the study drug to the beginning of the colonoscopy</description>
          <population>Patients who did not reach the endpoint are excluded from this analysis.</population>
          <units>minutes</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="31"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.0" lower_limit="4.0" upper_limit="8.0"/>
                    <measurement group_id="O2" value="18.3" lower_limit="17.5" upper_limit="21.0"/>
                    <measurement group_id="O3" value="19.0" lower_limit="19.0" upper_limit="19.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Fully Alert</title>
        <description>Time to first of 3 Modified Observer's Assessment of Alertness/Sedation (MOAA/S) scores of 5 after the end of colonoscopy procedure (colonoscope out) and after the last injection of study drug</description>
        <time_frame>From the last injection of the study drug AND from end of colonoscopy until the patient has recovered to fully alert</time_frame>
        <population>Patients who did not reach the endpoint are censored at last observation.</population>
        <group_list>
          <group group_id="O1">
            <title>Remimazolam</title>
            <description>Remimazolam 2.5 - 5.0 mg initially, followed by 1.25 - 2.5 mg top-up doses as required to maintain sedation.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo administered in double-blind manner.</description>
          </group>
          <group group_id="O3">
            <title>Midazolam</title>
            <description>Midazolam 1.0 mg initially, followed by 0.5 mg top-up doses as required to maintain sedation.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Fully Alert</title>
          <description>Time to first of 3 Modified Observer's Assessment of Alertness/Sedation (MOAA/S) scores of 5 after the end of colonoscopy procedure (colonoscope out) and after the last injection of study drug</description>
          <population>Patients who did not reach the endpoint are censored at last observation.</population>
          <units>minutes</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="31"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>After last dose of trial or rescue sedative</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.0" lower_limit="8.8" upper_limit="12.0"/>
                    <measurement group_id="O2" value="18.0" lower_limit="14.0" upper_limit="25.0"/>
                    <measurement group_id="O3" value="18.8" lower_limit="15.0" upper_limit="26.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>After the end of colonoscopy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.0" lower_limit="2.0" upper_limit="4.0"/>
                    <measurement group_id="O2" value="5.3" lower_limit="4.0" upper_limit="12.0"/>
                    <measurement group_id="O3" value="7.0" lower_limit="4.0" upper_limit="12.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Treatment-emergent Adverse Events (TEAEs) were collected from first dose of study drug medication until Day 4 (+ 3 days), and were followed until events resolved, became stable, or could be explained by another known cause(s)</time_frame>
      <desc>Total number of participants affected with Other (Not Including Serious) Adverse Events represents any participant in the trial with a TEAE. The number of participants with Preferred Term (PT)TEAEs represents participants with TEAEs reported with a threshold of 5% in any of the arms</desc>
      <group_list>
        <group group_id="E1">
          <title>Remimazolam</title>
          <description>Remimazolam 2.5 - 5.0 mg initially, followed by 1.25 - 2.5 mg top-up doses as required to maintain sedation.</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Placebo administered in double-blind manner.</description>
        </group>
        <group group_id="E3">
          <title>Midazolam</title>
          <description>Midazolam 1.0 mg initially, followed by 0.5 mg top-up doses as required to maintain sedation.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 18.0</default_vocab>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 18.0</default_vocab>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="28" subjects_at_risk="31"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="16"/>
                <counts group_id="E3" subjects_affected="26" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Bradycardia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Respiratory rate decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Respiratory acidosis</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="31"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="31"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="16"/>
                <counts group_id="E3" subjects_affected="17" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="31"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="16"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Diastolic hypertension</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="31"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Diastolic hypotension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Systolic hypertension</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="31"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>At least 45 days prior to submission of communications, sponsor shall review and comment on the communications. Sponsor shall have the right to require institution and investigator to remove specifically identified confidential information and to delay the proposed publication an additional 45 days to enable sponsor to seek patent protection</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Trial Information</name_or_title>
      <organization>PAION UK Ltd</organization>
      <email>reg_paion@paion.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

